News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
AMPLIFY clinical trial to read out 3Q19 PHREEDOM clinical trial to read out 4Q19 FREMONT, Calif. , Aug. 9, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with
View HTML
Toggle Summary Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
FREMONT, Calif. , May 30, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today announced that Mike Raab , president and chief executive
View HTML
Toggle Summary Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Two Pivotal Phase 3 readouts in 2H 2019 FREMONT, Calif. , May 7, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business
View HTML
Toggle Summary Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
FREMONT, Calif. , March 14, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), today announced the appointment of Geoffrey A. Block , M.D., Vice President, Nephrology at Reata and former Director of Clinical Research in the Denver Nephrology Research Division at Colorado Kidney Care/Denver
View HTML
Toggle Summary Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
- Ardelyx's investigative agent for end-stage renal disease patients on dialysis represents first non-binder innovation to lower patients' phosphate levels, a critically important parameter that is correlated with morbidity and mortality - Ardelyx's approach leverages newly discovered pathway for
View HTML
Toggle Summary Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia FREMONT, Calif. , March 6, 2019 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal
View HTML
Toggle Summary Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
FREMONT, Calif. , Feb. 21, 2019 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:30 p.m. ET on Thursday, Feb.
View HTML
Toggle Summary Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Ardelyx to Receive a $5 Million Milestone Payment Company Narrows Timeline for its PHREEDOM trial and announces AMPLIFY, a new Phase 3 Trial evaluating tenapanor in combination with binders FREMONT, Calif. , Feb. 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) ( Ardelyx ) today announced that
View HTML
Toggle Summary Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
FREMONT, Calif. , Nov. 13, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that  the U.S. Food and Drug Administration ( FDA ) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with irritable bowel syndrome with constipation
View HTML
Toggle Summary Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 FREMONT, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights and financial results for the third quarter ended September 30, 2018 .
View HTML